MetaVia (NASDAQ:MTVA – Get Free Report) is expected to be issuing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.7333) per share for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.
MetaVia (NASDAQ:MTVA – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.08). On average, analysts expect MetaVia to post ($2.79) EPS for the current fiscal year and ($3.02) EPS for the next fiscal year.
MetaVia Price Performance
Shares of MTVA stock opened at $1.17 on Tuesday. The firm has a fifty day moving average of $1.52 and a two-hundred day moving average of $1.70. The firm has a market cap of $6.04 million, a P/E ratio of -0.36 and a beta of 1.24. MetaVia has a 1-year low of $0.97 and a 1-year high of $14.85.
Wall Street Analysts Forecast Growth
Several brokerages have recently commented on MTVA. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MetaVia in a research report on Monday, October 19th. HC Wainwright reiterated a “buy” rating on shares of MetaVia in a research note on Friday, July 10th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, MetaVia presently has an average rating of “Hold” and an average target price of $20.00.
View Our Latest Stock Report on MTVA
MetaVia Company Profile
MetaVia, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases. Its work is centered on conditions such as obesity, diabetes and other disorders associated with metabolic dysfunction.
The company’s activities primarily involve the discovery, development and clinical evaluation of potential drug candidates intended to address significant unmet medical needs in metabolic health. As a development-stage biotechnology company, MetaVia’s operations are focused on research programs and advancing therapies through clinical testing rather than on commercialized products.
Publicly available information provides limited detail about MetaVia’s corporate history, geographic operations and leadership.
Read More
- Five stocks we like better than MetaVia
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.
